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Abstract: Background: A number of controlled trials have examined the effect of zinc lozenges on the common cold but 
the findings have diverged. The purpose of this study was to examine whether the total daily dose of zinc might explain 
part of the variation in the results. 
Methods: The Medline, Scopus and Cochrane Central Register of Controlled Trials data bases were searched for placebo-
controlled trials examining the effect of zinc lozenges on common cold duration. Two methods were used for analysis: the 
P-values of the trials were combined by using the Fisher method and the results of the trials were pooled by using the 
inverse-variance method. Both approaches were used for all the identified trials and separately for the low zinc dose and 
the high zinc dose trials. 
Results: Thirteen placebo-controlled comparisons have examined the therapeutic effect of zinc lozenges on common cold 
episodes of natural origin. Five of the trials used a total daily zinc dose of less than 75 mg and uniformly found no effect. 
Three trials used zinc acetate in daily doses of over 75 mg, the pooled result indicating a 42% reduction in the duration of 
colds (95% CI: 35% to 48%). Five trials used zinc salts other than acetate in daily doses of over 75 mg, the pooled result 
indicating a 20% reduction in the duration of colds (95% CI: 12% to 28%). 
Conclusions: This study shows strong evidence that the zinc lozenge effect on common cold duration is heterogeneous so 
that benefit is observed with high doses of zinc but not with low doses. The effects of zinc lozenges should be further 
studied to determine the optimal lozenge compositions and treatment strategies. 
Keywords: Meta-analysis, randomized controlled trials, respiratory infections, zinc. 
INTRODUCTION 
  Zinc has various effects on the immune system and its 
deficiency increases the risk of infections [1,2]. In develop-
ing countries, there is evidence that zinc supplementation 
may reduce the risk of the common cold and pneumonia in 
children [2-4]. Although such studies indicate that zinc plays 
an important role in the immune system, those findings 
cannot be extrapolated to the developed countries where 
there is no wide spread zinc deficiency. For example, in 
France and in the UK, multivitamin-mineral tablets 
containing 15 or 20 mg/day of zinc had no effect on the 
incidence of respiratory infections of elderly people [5,6]. 
  Interest in zinc lozenges (tablets intended to be dissolved 
slowly in the mouth) for treating the common cold started 
from the serendipitous observation that a cold of a 3-year-old 
girl with leukemia disappeared when she dissolved a 
therapeutic zinc tablet in her mouth instead of swallowing it 
[7]. This finding led to a series of controlled trials which 
have produced conflicting results. The composition of zinc 
lozenges has varied and some of them contained substances 
which bind zinc ions tightly. Therefore, a low level of free 
zinc ions has been considered as one potential factor that 
might explain divergence in the results [8-15]. The mode of  
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action of zinc in the oral cavity is not known. However, the 
fundamental questions in evaluating a potential treatment 
should be efficacy, safety and cost, whereas biological 
explanations and the effects on surrogate outcomes should be 
secondary issues [16-18]. 
  The purpose of this systematic review is to examine the 
relationship between the total daily dose of zinc from the 
lozenges and the effect of the zinc lozenges on the duration 
of colds in patients who had natural common cold infections.  
METHODS 
Search of the Trials 
  Ovid MEDLINE (November 24, 2010) was searched 
using the free search terms “zinc” and “lozenge$” which 
retrieved 67 records. The same search terms were used for 
SCOPUS (November 24, 2010; 107 records) and for the 
Cochrane Central Register of Controlled Trials (CENTRAL; 
November 24, 2010; 20 records). No language restrictions 
were used in the searches. The reference lists of the trials and 
reviews identified were also perused. 
  This systematic review was restricted to trials examining 
the therapeutic effect of zinc lozenges on natural common 
cold infections. As an inclusion criterion, a concurrent 
placebo group was required, because clinically relevant 
common cold outcomes are largely subjective, and explicitly 
different interventions (i.e., no placebo in one arm) might 
bias the comparison. Studies with adults and children were 
both included. Rather than exclude non-randomized trials, 52    The Open Respiratory Medicine Journal, 2011, Volume 5  Harri Hemilä 
their influence was considered in a sensitivity analysis. 
Eleven publications fulfilling the inclusion criteria were 
identified [7,19-28] (Table 1, see Supplementary Material 1 
for a flow diagram of the search and Supplementary Material 
2 for a summary of the main characteristics of the included 
trials). One publication reported three zinc lozenge arms 
which were compared with one placebo arm [23], so that the 
number of identified zinc lozenge vs placebo comparisons 
was 13 (Table 1 ). One zinc lozenge study was excluded 
because the lozenge was used with a nasal spray and thus the 
comparison was not specific to the lozenge [29]. No protocol 
was written for this systematic review. 
  To confirm that there are no further trials in addition to 
those listed in Table 1, a cited reference search was also 
carried out (Web of Science, November 24, 2010) using the 
11 identified publications as cited references, because 
inaccuracy in coding might hamper the identification of 
relevant trials in MEDLINE, SCOPUS and CENTRAL. 
Since all new trials on a given topic most probably refer to 
one or more earlier trials on the same topic, this provides a 
further approach for searching the literature. No additional 
trials were identified by screening the 269 publications that 
cited the zinc lozenge reports of Table 1. 
Calculation of the Daily Zinc Dosage 
  The total daily dose of elemental zinc from the lozenges 
was calculated as the product of the zinc dose per lozenge 
and the counted or planned number of lozenges per day 
(Table  1; see Supplementary Material  2 for the calculat-
ions). In six trials, the number of lozenges was counted [20-
22, 24-26]. In the other trials, the usage recommended was 
the basis for the calculation of the total zinc dosage; for 
example, description of the dosage as “every 2 hr awake” 
was interpreted as 9 times per day. 
Statistical Methods 
  Some earlier reviews on the effect of zinc lozenges on 
common cold symptoms calculated the effect of zinc on 
common cold duration on the absolute scale, i.e., as the 
difference in days in the cold duration [11,13,14]. However, 
Table 1 shows a substantial variation in the duration of colds in 
the placebo groups, from 5.1 days [22] to 9.0 days [27] and 10.8 
days [7]. Although part of this variation is evidently caused by 
random variation, it is also caused by actual variations in the 
severity of disease in different patient groups and in differences 
in outcome definitions. In this study, the relative effect of zinc 
on the common cold duration was calculated in percentages, 
because the relative effect partly adjusts for the variations 
between patient groups and outcome definitions. Previously, the 
calculation of relative effect instead of the absolute effect led to 
stronger evidence that vitamin C supplementation decreases the 
duration of the common cold [30,31]. Therefore, the relative 
effect is used in the Cochrane review on vitamin C and the 
common cold [32]. 
  Two different approaches were used to evaluate the 
findings of the zinc lozenge trials: 1) combining the P-values 
by using the Fisher method [33,34] and 2) pooling the study 
results by using the RevMan program (version 5) [35]. 
Table 1.  Effect of Zinc Lozenges on Common Cold Episodes of Natural Origin 
 
Study [Ref.]  No. of Participants  Zn Dose 
Per Day (mg)
a 
Average Duration of Colds (Days)
b 
Zn/Placebo  The Effect of Zn  P
b 
(1-Tail)  –2ln(P) 
Eby et al.1984 [7]  65  207  3.9/10.8
c  -64%
c  0.0005
c  15.2 
Smith et al.1989 [19]  110  207  5.9/6.3
d 
5.5/6.9
d  -22%
d  0.5
d 
0.01
d  1.4 
Godfrey et al. 1992 [20]  73  192  4.9/6.1  -21%  0.024  7.4 
Prasad et al. 2008 [21]  50  92  4.0/7.1  -44%  610
–13  56.3 
Petrus et al. 1998 [22]  101  89  3.8/5.1  -26%  0.0033  11.4 
Turner at al. A 2000 [23]  139  80  6.0/5.5    0.5  1.4 
Mossad et al.1996 [24]  99  80  4.4/7.6  -42%  0.0005  15.2 
Prasad et al. 2000 [25]  48  80  4.5/8.1  -44%  210
–9  40.0 
Turner et al. B 2000 [23]  139  69  5.5/5.5    0.5  1.4 
Douglas et al. 1987 [26]  58
e  64 12.1/7.7    0.96  0.1 
Macknin et al. 1998 [27]   247 45  9.0/9.0    0.5  1.4 
Weismann et al. 1990 [28]  130 45  7/6    0.5  1.4 
Turner et al. C 2000 [23]  143  30  6.0/5.5    0.5  1.4 
aCalculation of the daily dose of zinc: see  Supplementary Material  2. 
bThe outcome is the mean or median of common cold duration, except when otherwise stated. The P-values were recalculated when appropriate data was reported in the paper. 
cEby et al. [7] did not report the mean or median duration, but estimated the time at which half of the participants were cured from an exponential fit of the results. The P-value at this 
table was calculated by using the Fisher exact test for the number of participants reporting no symptoms after the 7-day trial: 32/37(86%) and 13/28(46%) in the zinc and placebo 
groups, respectively. 
dSmith et al. [19] reported that “subjects taking zinc gluconate had lower severity scores than those in the corresponding placebo group on days 4 to 7 of treatment. This difference is 
statistically significant (P = 0.02).” From Smith et al.’s fig. 2, the days needed for 80% reduction in the severity score, which occurred in the 4 to 7 day time range, was measured 
thereby transforming the effect to the time scale for this table. The upper line (5.9/6.3) gives the interpolated time point when 40% of participants had become asymptomatic from 
Smith et al.'s fig. 1; the placebo participants were not followed until half of them had become asymptomatic. To be conservative, P = 0.5 was used for calculating the –2log(P), and 
not the small P-value corresponding to the difference in severity scores on days 4 to 7. 
eThe number of treatment courses was 63; some of the 58 participants had more than one cold episode. Zinc Lozenges and the Common Cold  The Open Respiratory Medicine Journal, 2011, Volume 5    53 
  The P-values of Table 1  were combined by using the 
Fisher method, which is based on the relation that –2log(P) 
follows the 
2-distribution with 2 degrees of freedom, with 
the P-value given in the 1-tailed form [33,34]. Thus, the   
–2log(P) values for all selected trials (N trials) are added, 
and the total follows the 
2-distribution with N2 degrees of 
freedom, which gives the combined P-value for all the N 
trials. When appropriate data was published, the accurate   
P-values were calculated. For trials for which the P-value 
was not reported and could not be calculated, P = 0.5 was 
used, which conservatively assumes equality between the 
zinc lozenge and the placebo. Extracted or derived P-values 
are described in Supplementary Material 2. The combined  
P-values for selected groups of trials are calculated in Table 2. 
Table 2.  The Effect of Zinc Lozenges on the Duration of the 
Common Cold: Combining the P-Values of the 
Placebo-Controlled Trials 
 
Trials Being Combined  No. of Trials  
2  df P 
All trials  13  154.0  26 10
–19 
Low Zn dose (<75 mg/day)  5  5.7  10  0.8 
High Zn dose (>75 mg/day)  8  148.3  16 10
–22 
 Zn-acetate [21,22,25]  3  107.7  6 10
–20 
 not Zn-acetate [7,19,20,23,24]  5  40.6  10 10
–5 
The P-values of the individual trials are combined by using the Fisher method (see the 
Methods section). The combined 
2 value is calculated from the –2ln(P) values on the 
right side of Table 1. The combined P-values are separately calculated for low dose and 
high dose trials. Finally, the high dose trials are divided to those which used zinc 
acetate and to those which used zinc salts other than acetate. 
 
  The benefit of the Fisher method of combining P-values 
is that it can be used for results that are reported on different 
scales and when limited data is available [33,34]. For 
example, if one trial reports the duration with its standard 
deviation (SD) and another trial reports the number of 
participants who had colds lasting over 7 days, both of them 
measure the effect on common cold duration, but on 
different scales. Although no combined effect estimate can 
be calculated for such trials, the P-values of those two trials 
can be combined by using the Fisher method. Furthermore, if 
there is no difference between the study groups e.g. on the 
basis of considerable overlap in the survival graphs - even 
though mean and SD are not reported - the study can be 
included without making any assumptions about the mean 
and SD, since the lack of difference corresponds to P(1-tail) 
= 0.5. Some of the zinc lozenge trials did not report the mean 
duration of colds and its SD, but they reported the P-values 
for the comparison of the zinc and placebo groups. For these 
reasons, the Fisher method was used as one approach to test 
whether there is a difference between zinc and placebo 
groups. 
  A forest plot (Fig. 1 ) is an efficient way to show the 
results of several trials, and it was used as a second 
approach. However, this approach needs the mean and SD 
values for the zinc and placebo groups. Only three zinc 
lozenge studies reported the SD values [21,22,25]. One study 
reported the t-value for the comparison [20] and another 
reported the P-value [26], and the corresponding SD-values 
were calculated. Nine comparisons were reported as survival 
graphs, i.e. the number of participants who remained ill or 
were recovered as a function of time [7,19,23-25,27,28]. 
These graphs were measured and transformed to the 
distribution of the duration of colds, which yielded estimates 
of the mean and SD (Supplementary Material 3). In the 
analysis of the graphs, several imputations were needed, 
because the graphs usually did not continue until all patients 
were recovered. Since the forest-plot analysis required a 
number of subjective decisions, the Fisher method (above) 
provided a useful parallel method, because it required less 
subjective decisions. Nevertheless, sensitivity analyses 
showed that the conclusions of Fig. (1) are robust to 
variation in the imputation approach (Supplementary 
Material 3). The forest plot (Fig. 1) was calculated by using 
the RevMan program of the Cochrane Collaboration (version 
5), using the inverse-variance fixed-effect option [35]. The 
heterogeneity between trials was assessed by using the 
2 and 
I
2 -tests [36]. The I
2 -test examines the percentage of total 
variation across studies, that is due to heterogeneity rather 
than chance. A value of I
2 greater than about 75% indicates a 
high level of heterogeneity. 
RESULTS 
  Thirteen placebo-controlled comparisons have examined 
the therapeutic effect of zinc lozenges on the duration of 
common cold episodes of natural origin (Table 1 and Fig 1). 
The total number of common cold episodes in these trials 
was 1407. All the 13 comparisons were double-blind, 
although this feature was not a selection criterion. Because 
of double-blinding, all trials used allocation concealment. 
Weissman et al. [28] used consecutive allocation, but all the 
other trials were randomized. All studies examined young 
and middle-aged adults, except the Macknin et al. [27] trial, 
which examined schoolchildren. 
 In  Table  1, the trials are ordered by the total daily 
quantity of elemental zinc obtained from the lozenges. There 
is a seven-fold variation in the total daily dose of zinc. There 
is also a considerable variation in the results. Seven 
comparisons found a statistically significant benefit from 
zinc lozenges, but six did not. 
 Smith  et al. [19] did not observe a difference between the 
study groups in the duration of colds; however, they did find 
a significant reduction in the severity scores on days 4 to 7 of 
treatment with P(1-tail)=0.01. Eby et al. [7] did not report 
the mean or median duration, but they did report the number 
of participants who had no symptoms at the end of the 7-day 
trial, an outcome used for calculating the P-value in Table 1. 
The duration of colds given in Table 1 for the Eby trial is 
based on the exponential model which they used to estimate 
the time at which half of their patients were cured. 
 Table 1  shows that a substantial proportion of the 
variation in the results can be explained by the daily zinc 
dosage. None of the five comparisons that used less than 75 
mg/day of zinc found an effect of zinc lozenges, whereas 
seven of the eight comparisons which used over 75 mg/day 
of zinc found a statistically significant benefit, although the 
benefit in the Smith et al. trial was restricted to the symptom 
severity at the late phase of the colds. 
  The P-values of the individual trials are combined by 
using the Fisher method in Table 2. Combining the P-values 
of all the 13 comparisons provides very strong evidence that 54    The Open Respiratory Medicine Journal, 2011, Volume 5  Harri Hemilä 
the zinc lozenge and placebo groups differ over all the trials. 
However, the benefit of zinc is restricted to trials where the 
dose was greater than 75 mg/day. A significant effect by zinc 
lozenges is seen separately in three high-dose trials where 
zinc acetate was used and in five high-dose trials which used 
zinc salts other than acetate. 
 Fig.  (1) shows the forest plot of all 13 zinc lozenge 
comparisons. There is a highly significant heterogeneity 
between the 13 trials on the basis of both the 
2 and I
2-tests, 
with 
2(12 df) = 109 and I
2 = 89%. The trials are divided into 
the low and high dose subgroups as in Table 2 and the two 
subgroups are considerably different in their estimate of the 
zinc lozenge effect. 
  In the low-dose trials, there is no evidence of 
heterogeneity and all the low-dose comparisons are 
consistent with no effect of zinc lozenges. In the eight high-
dose trials, the zinc lozenges reduce the duration of colds by 
32% (95% CI: 27% to 37%) but there is strong evidence of 
heterogeneity within this high-dose subgroup (
2(7 df) = 46 
and I
2 = 85%) (Fig. 1). 
  Pooling the three high dose (>75 mg/day) zinc acetate 
trials gives a mean effect of 42% reduction in the duration of 
colds and no heterogeneity is seen between these trials 
(Table 3). Five high dose (>75 mg/day) trials used zinc salts 
other than acetate [7,19,20,23,24]. None of them reported the 
SD value, but SD was estimated from the published survival 
curves (Supplementary Material 3) [7,19,23,24] or the 
reported t-value [20]. Pooling these five non-acetate trials 
gives a mean effect of 20% (95% CI: 12% to 28%) reduction 
in the duration of colds. However, there is significant 
heterogeneity between these five non-acetate trials   
(
2(4 df) = 25.3, P = 0.0001; I
2 = 84%). 
  Sensitivity analysis by the methodological quality of the 
trials was not carried out because all trials were double-
blind, which also means that all used concealed allocation. 
One trial used consecutive allocation [28], but in a double-
blind trial it is not reasonable to assume that consecutive 
 
Fig. (1). The effect of zinc lozenges on the duration of the common cold. The trials are in the same order as in Table 1, from the highest daily 
dose of zinc to the lowest dose. They are divided into the same high dose and low dose subgroups as in Table 2. In the forest plot on the right 
side, the vertical line indicates the placebo level. The horizontal line indicates the 95% CI for the effect and the square in the middle of the 
horizontal line indicates the point estimate of the effect in the particular trial. Three diamond shapes indicate the pooled effects and their 95% 
CI:s for the two subgroups and for all trials. The duration of colds has been transformed to the relative scale so that the duration in the 
placebo group is given the value of 100%. Thereby the difference between zinc and placebo groups directly indicates the effect of zinc 
lozenges in percentages. See Supplementary Material 2 and Supplementary Material 3 for the extraction of the data and for the calculation of 
the relative mean and SD values for the common cold duration. Zinc Lozenges and the Common Cold  The Open Respiratory Medicine Journal, 2011, Volume 5    55 
allocation would lead to systematic bias between the study 
groups. Furthermore, the trial [28] had low dose of zinc and 
therefore its exclusion would strengthen, and not weaken, the 
evidence that zinc lozenges differ from the placebo. 
  All three trials which used zinc acetate in doses higher 
than 75 mg/day (Table 3 ) were methodologically rigorous 
randomized trials [21,22,25]. In the Petrus trial, only one 
participant was lost from follow-up [22]. In the first Prasad 
trial, two participants in the placebo group dropped out on 
day 2 [25], whereas there were no drop-outs in the second 
Prasad trial [21]. No sensitivity analysis was done in this 
subgroup. 
  There is substantial heterogeneity within the five high-
dose non-acetate trials. Sensitivity analysis was done leaving 
out the Eby et al. [7] and Smith et al. [19] trials, which 
excluded a large number of randomized participants, 45% 
and 36%, respectively. Furthermore, over half of the 
common cold durations needed to be imputed to include 
these trials in Fig. (1). When these two trials were excluded 
from the high-dose non-acetate subgroup, the remaining 
three trials lead to 22% (95% CI: 11 to 32%) decrease in the 
duration of colds. This confidence interval is essentially the 
same as that for all the five non-acetate trials, see above. 
Thus, exclusion of these two trials has no influence on 
conclusions. 
DISCUSSION 
Dose-Response Relation Between the Quantity of Zinc 
and the Effect on the Common Cold Duration 
  No effect of zinc lozenges was seen in trials where the 
total daily dose of zinc was less than 75 mg, whereas the 
majority of trials with higher zinc doses did find benefit 
(Tables 1 to 3, Fig. 1). The level of 75 mg per day should not 
be considered as an exact biological limit, but as a pragmatic 
cut-off point for dichotomizing the trials into low and high 
dose trials in these meta-analyses. Nevertheless, the 
conclusion that zinc lozenges differ from the placebo does 
not depend on the arbitrary cut-off limit because pooling all 
the 13 double-blind comparisons also shows that zinc 
lozenges differ from the placebo (Table 2 and Fig. 1). 
Lozenge Composition and the Level of Free Zinc Ions 
  In these meta-analyses, the dose-response relation was 
examined using the total daily zinc dose as the explanatory 
variable. However, this is a simplified approach because 
some lozenges contained substances which bind zinc ions 
tightly, such as citrate, tartrate or glycine, which decrease the 
level of free zinc ions. Thus, even though the same dose of 
zinc is used in two different lozenges, other constituents may 
lead to substantial differences in the levels of free zinc ions. 
  Previously, several authors discussed the availability of 
zinc ions as a factor that may potentially modify the effect of 
zinc lozenges on the common cold [8-15]. Martin assumed 
that sucking a zinc-citric acid lozenge would decrease the pH 
of saliva to 2.3, pointing out that citrate would not form a 
complex with zinc ion at such a low pH level [10]. However, 
Zarembo  et al. carried out an experiment with 18 
participants, finding that sucking a zinc-citric acid lozenge 
resulted in saliva pH levels ranging between 3.2 and 5.0 
[15]. At such pH levels citrate binds zinc ions as shown by 
the published binding curves [10,11,13,14]. 
  The solution chemistry of zinc complexes gives further 
understanding of the differences between the zinc trials. Two 
research groups, both using lozenges containing 23 mg of 
elemental zinc, examined the effect of zinc lozenges on 
experimentally induced rhinovirus colds. Al-Nakib et al. 
[37,38] found a significant benefit using the lozenges, 
whereas Farr et al. found none [39]. However, Farr's lozenge 
contained 2% citric acid whereas Al-Nakib's lozenge did not, 
a difference in lozenge composition which could explain the 
divergent results [11-14]. 
  Among the trials with natural common cold episodes in 
Table 1, Godfrey et al. [20] administered a high dose of zinc, 
but glycine in the lozenge bound 80% of the zinc ions to 
complexes [11-14], which could explain the rather small 
benefit compared with the other trials which used high doses 
of zinc (Table 1 ). Turner et al. found no effect using 69 
mg/day of zinc acetate [23]. However, Eby pointed out that 
Turner's lozenges contained palm kernel and cotton seed 
oils, and at the high temperature used in the manufacture of 
the lozenges, these ingredients react with zinc ions making 
insoluble compounds [40]. The lozenge used by Douglas   
et al. [26] contained tartaric acid, which binds zinc [11,13,14]. 
  Although the solution chemistry of zinc ions may offer 
more detailed explanations of the variation between the trial 
results, the power of the dose-response analysis can be seen 
even by counting the total daily dosage of elemental zinc 
obtained from the lozenges (Tables 1 and 2; Fig. 1). 
Table 3.  Pooling the Results of the High Dose Zinc Acetate Trials 
 
Intervention 
Zinc Placebo  Trial 
No. of Colds  Mean Duration  
of Colds (Days)  SD  No. of Colds  Mean Duration  
of Colds (Days)  SD 
Effect of Zinc Acetate on Common Cold Duration
a 
(95% CI) 
Petrus et al. 1998 [22]
b  52 3.80  1.63  49 5.10  2.96  -26% (-44%, -7%) 
Prasad et al. 2000 [25]  25 4.5  1.6  23 8.1  1.8  -44% (-56%, -33%) 
Prasad et al. 2008 [21]  25 4.00  1.04  25 7.12  1.26  -44% (-53%, -35%) 
Pooled  results  102     97     -42%  (-48%,  -35%) 
aThere is no evidence of heterogeneity over these three trials: 
2(2 df) = 3.5 (P = 0.2), I
2 = 43%. Calculations were done by using the RevMan program [35]. 
bPetrus et al. [22] reported the results inaccurately to only one decimal place, giving 3.8 and 5.1 for the mean duration of colds and 0.2 and 0.4 for the SE of the mean in the zinc and 
placebo groups, respectively. These more accurate figures were kindly provided by Ken Lawson (March 4, 2009). 56    The Open Respiratory Medicine Journal, 2011, Volume 5  Harri Hemilä 
Safety of Zinc 
  In several common cold trials, the zinc lozenges caused 
acute adverse effects, such as bad taste and constipation, but 
none of the trials reported long term harm. Furthermore, 
several of the reported adverse effects, in particular on taste, 
may have been caused by the specific lozenge composition, 
and may not reflect the effects of zinc ions per se [13]. In the 
most recent trial on zinc acetate, there were no significant 
differences between the zinc and placebo groups in the 
occurrence of adverse effects although the daily dose was 92 
mg [21]. 
  For certain patients, zinc has been administered at high 
doses, 150 mg/day, for therapeutic purposes for months or 
years [41-45]. Deficiency of copper has been reported as a 
consequence of long-term zinc supplementation [44,45], but 
a six-week experiment did not find any effect from 150 
mg/day of zinc on plasma copper levels [46]. On the basis of 
these long-term studies with high zinc doses, there does not 
seem to be any basis for assuming that treating the common 
cold for a week with high doses of zinc in the form of 
lozenges would cause unanticipated harm. A patient 
suffering from acute adverse effects such as bad taste can 
simply stop taking the lozenges. 
Implications for Further Research 
 Table  1 suggests that the benefit of zinc lozenges perhaps 
can be obtained with doses substantially lower than Eby et al. 
used in the first trial on the topic [7]. Four trials used 80 to 
92 mg of zinc per day and observed significant benefit 
(Table 1 ). Three of them used lozenges containing zinc 
acetate (Table 3), which does not form complexes with zinc 
ions [13,14]. Obviously, new trials should be carried out to 
confirm the benefit of zinc acetate lozenges at a dosage of 
about 80 mg per day, and to examine whether even lower 
daily doses in appropriately formulated lozenges might be 
effective. 
Other Reviews on the Effect of Zinc Lozenges on the 
Common Cold 
  Two groups of reviewers concluded that there is no 
evidence that zinc lozenges are beneficial against colds. 
Jackson  et al. [47,48] found statistically significant 
heterogeneity between the zinc trials. They calculated a 
pooled estimate of effect, although the evidence of 
heterogeneity seriously challenges the validity of any single 
overall estimate. Faced with heterogeneous results, the main 
focus of the reviewers should be on trying to understand the 
sources of the heterogeneity [49]. Although Jackson 
suggested that some of the negative results might be 
explained by low zinc ion availability, they did not examine 
the issue. 
  In another systematic review, Caruso et al. used the 
quality scoring approach, so that for the trials identified they 
gave one point for each of 11 quality items if it was satisfied 
[50]. Only four of the identified trials obtained the maximum 
of 11 points, and Caruso et al. suggested that the positive 
findings in the zinc trials might be explained by 
methodological faults. However, such a quality scoring 
approach is discouraged, for example, in the Cochrane 
Handbook, which states that “the use of scales for assessing 
quality or risk of bias is explicitly discouraged in Cochrane 
reviews. While the approach offers appealing simplicity, it is 
not supported by empirical evidence” [18]. 
  One major problem of quality scoring is the focus on 
reporting in contrast to the scientific quality of the trial. For 
example, Caruso et al. gave one point if the study reported 
“measurement of dropout rate”. This means that a trial can 
report high dropout rate, indicating low scientific quality, yet 
Caruso et al. would allot a point because the high dropout 
rate was explicitly reported. Caruso et al. also gave a point 
for “double blinding” because “unblinded studies are biased 
towards finding a treatment effect” [50]. However, such a 
statement is invalid, because a large meta-analysis of 
controlled trials found no association between double 
blinding and the effect of intervention [51]. Most of Caruso 
et al.'s other quality items involve similar problems. 
Furthermore, Caruso et al. did not discuss the possibility that 
the level of free zinc ions might have an effect on the trial 
results, nor did they refer to any of the numerous papers that 
have discussed this issue [8-15,52]. 
  Finally, both Jackson et al. [47,48] and Caruso et al. [50] 
proposed that the benefit of zinc lozenges in some trials 
might be explained by the placebo-effect. To support their 
proposal, both groups referred to Chalmers’ review on 
vitamin C and the common cold, which suggested that the 
differences between vitamin C and placebo groups were, 
paradoxically, caused by the placebo effect [53]. However, 
Chalmers' review was shown to be erroneous over a decade 
ago. For example, the figures in his main table were not 
consistent with the original study reports and he made errors 
in calculation [30,31,54]. Thus, the conclusions about the 
effects of zinc lozenges in this study diverge from the 
conclusions of two earlier reviews, but there are explicit 
reasons for the divergence in the conclusions. 
  Goodwin and Tangum [16] argued that within academic 
medicine there has been systematic bias against the concept 
that under some conditions micronutrients might be 
beneficial at levels higher than the minimum required to 
avoid classic deficiency diseases. Dismissing the randomized 
double-blind trials in which zinc lozenges significantly 
reduced the duration of colds gives further support to their 
thesis. 
  While this paper was under review, a Cochrane 
systematic review on zinc and the common cold was 
published [55]. There are many differences between this 
paper and the Cochrane review. While this paper strictly 
limits to zinc lozenges, the Cochrane review combines zinc 
lozenge trials with ordinary zinc tablet trials. However, it is 
possible that benefits of zinc tablets [2-4] are caused by 
particularly low initial zinc intakes of the participants, 
whereas the effects of zinc lozenges may be caused by local 
effects in the oral cavity. Nevertheless, the Cochrane review 
also concluded that there is evidence of benefit of zinc 
administration. 
CONCLUSIONS 
  Controlled trials that have examined the effect of zinc 
lozenges on common cold symptoms have reported 
divergent results. This meta-analysis shows that a large part 
of the divergence can be explained by the variation in the 
total daily dose of zinc that the person obtained from the 
lozenges. Many trials with daily zinc doses of over 75 mg Zinc Lozenges and the Common Cold  The Open Respiratory Medicine Journal, 2011, Volume 5    57 
have found significant reduction in the duration of colds. 
Zinc lozenges have caused adverse effects, such as bad taste, 
but there is no evidence that they would cause long term 
harm. Since a large proportion of trial participants have 
remained without adverse effects, zinc lozenges might be 
useful for them as a treatment option for the common cold. 
More research is needed on zinc lozenges to find optimal 
lozenge compositions and treatment strategies. 
SUPPLEMENTARY MATERIAL 
  This article contains supplementary material and it can be 
viewed at publisher’s website. 
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